Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CO Global Cord Blood	$1.35	$1.49	$2.03 ▼ $5.50	$164.09M	0.16	216,519 shs	N/A
DNAA Social Capital Suvretta Holdings Corp. I	$14.07	$11.74	$9.07 ▼ $17.44	$360.76M	-0.02	182,488 shs	4.63 million shs
JYNT Joint	$12.08 -1.6%	$11.71	$7.31 ▼ $16.48	$180.48M	1.59	89,722 shs	40,270 shs
OPT Opthea	$3.64 +6.1%	$3.56	$1.60 ▼ $4.42	$212.58M	1.19	23,382 shs	5,867 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CO Global Cord Blood	0.00%	+8.00%	-10.00%	+11.57%	-54.81%
DNAA Social Capital Suvretta Holdings Corp. I	0.00%	0.00%	0.00%	0.00%	0.00%
JYNT Joint	-2.46%	+2.16%	-3.46%	+30.78%	-18.89%
OPT Opthea	+2.08%	+0.29%	-10.44%	+30.42%	-2.56%

The Hard Truth About Investing For Retirement (Ad)

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CO Global Cord Blood	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNAA Social Capital Suvretta Holdings Corp. I	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JYNT Joint	1.3846 of 5 stars	3.2	1.0	0.0	0.0	0.0	1.7	1.9
OPT Opthea	1.4485 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CO Global Cord Blood	N/A	N/A	N/A	N/A
DNAA Social Capital Suvretta Holdings Corp. I	N/A	N/A	N/A	N/A
JYNT Joint	2.33	Hold	$21.50	77.98% Upside
OPT Opthea	3.00	Buy	$14.00	284.62% Upside

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CO Global Cord Blood	$1.24B	0.13	$0.32 per share	4.19	$6.34 per share	0.21
DNAA Social Capital Suvretta Holdings Corp. I	N/A	N/A	N/A	N/A	($0.33) per share	N/A
JYNT Joint	$117.70M	1.53	$0.70 per share	17.35	$1.68 per share	7.19
OPT Opthea	$110K	1,932.51	N/A	N/A	($0.10) per share	-36.40

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CO Global Cord Blood	$79.04M	$0.64	2.11	∞	N/A	N/A	N/A	N/A	N/A
DNAA Social Capital Suvretta Holdings Corp. I	-$2.44M	N/A	0.00	∞	N/A	N/A	N/A	-3.32%	N/A
JYNT Joint	-$9.75M	-$0.66	N/A	24.16	N/A	-8.19%	7.80%	2.65%	5/2/2024 (Confirmed)
OPT Opthea	-$142.52M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest JYNT, OPT, DNAA, and CO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/2/2024	N/A	JYNT Joint	-$0.03	N/A	+$0.03	N/A	N/A	N/A
3/7/2024	Q4 2023	JYNT Joint	$0.03	$0.07	+$0.04	$0.89	$29.63 million	$30.61 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CO Global Cord Blood	$0.08	5.93%	N/A	12.50%	N/A
DNAA Social Capital Suvretta Holdings Corp. I	N/A	N/A	N/A	N/A	N/A
JYNT Joint	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CO Global Cord Blood	N/A	N/A	N/A
DNAA Social Capital Suvretta Holdings Corp. I	N/A	0.09	0.09
JYNT Joint	0.08	1.32	1.32
OPT Opthea	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
CO Global Cord Blood	N/A
DNAA Social Capital Suvretta Holdings Corp. I	N/A
JYNT Joint	76.88%
OPT Opthea	55.95%

Insider Ownership

Company	Insider Ownership
CO Global Cord Blood	0.50%
DNAA Social Capital Suvretta Holdings Corp. I	N/A
JYNT Joint	4.00%
OPT Opthea	3.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CO Global Cord Blood	1,202	121.55 million	N/A	No Data
DNAA Social Capital Suvretta Holdings Corp. I	4	25.64 million	N/A	Not Optionable
JYNT Joint	444	14.94 million	14.34 million	Optionable
OPT Opthea	24	58.40 million	56.53 million	Not Optionable

JYNT, OPT, DNAA, and CO Headlines

Source	Headline
	Opthea to Present at the OIS Retina Innovation Summit at ARVO globenewswire.com - April 25 at 9:00 AM
	Analyzing Opthea (NASDAQ:OPT) & Cellectis (NASDAQ:CLLS) americanbankingnews.com - April 23 at 1:44 AM
	Leerink Partnrs Research Analysts Decrease Earnings Estimates for Opthea Limited (NASDAQ:OPT) marketbeat.com - April 12 at 6:40 AM
	Opthea Appoints John Han, PharmD, as VP Medical Affairs globenewswire.com - April 8 at 6:42 PM
	Opthea Limited American Depositary Shares (OPT) nasdaq.com - April 5 at 1:37 PM
	Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference globenewswire.com - April 4 at 6:34 PM
	Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today msn.com - April 3 at 11:14 PM
	Opthea Appoints Sujal Shah to the Board of Directors globenewswire.com - April 3 at 5:39 PM
	7 Growth Stocks to Buy to Outperform the Nasdaq Index investorplace.com - April 3 at 9:53 AM
	Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024 globenewswire.com - March 19 at 6:00 AM
	End in sight as Opthea looks to be key player in US$10 billion wet AMD market msn.com - March 6 at 6:43 PM
	Opthea to Participate in the Leerink Partners Global Biopharma Conference globenewswire.com - March 5 at 5:08 PM
	Opthea Reports Half-Year Financial Results and Business Updates globenewswire.com - February 28 at 5:55 PM
	Opthea Limited (OPT) au.finance.yahoo.com - February 22 at 3:16 PM
	Opthea Limited: Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor finanznachrichten.de - February 20 at 5:31 AM
	Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor globenewswire.com - February 19 at 6:25 PM
	Opthea Limited: Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept finanznachrichten.de - February 14 at 10:23 AM
	Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept finance.yahoo.com - February 14 at 10:23 AM
	Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept globenewswire.com - February 14 at 7:00 AM
	Why Is Retinal Diseases-Focused Opthea Stock Trading Higher Today? msn.com - December 27 at 12:28 PM
	Opthea to receive $35M commitment and additional $50M funding msn.com - December 27 at 7:28 AM
	Opthea Limited ADRs Rise 31% on Raised Funding marketwatch.com - December 27 at 7:28 AM
	Opthea to Receive US$35M Commitment and Additional US$50M Funding finance.yahoo.com - December 27 at 7:28 AM
	Opthea Limited - ADR (OPT) Price Target Increased by 7.41% to 6.39 msn.com - December 16 at 2:18 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Best Bear Market Funds: Top 3 Investment Options to Consider
March 27, 2024 10:58 AM
View Best Bear Market Funds: Top 3 Investment Options to Consider
Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
How and When to Roll Your Options Positions?
March 27, 2024 9:32 AM
View How and When to Roll Your Options Positions?
Here are the Pros and Cons of Using Options Call Debit Spreads
April 11, 2024 11:03 PM
View Here are the Pros and Cons of Using Options Call Debit Spreads
Undervalued UnitedHealth Group Won’t Be For Long
April 16, 2024 10:53 AM
View Undervalued UnitedHealth Group Won’t Be For Long

All Headlines

Company Descriptions

Global Cord Blood

NYSE:CO

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Social Capital Suvretta Holdings Corp. I

NASDAQ:DNAA

Social Capital Suvretta Holdings Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology industry. The company was incorporated in 2021 and is based in Henderson, Nevada.

Joint

NASDAQ:JYNT

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Opthea

NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial